Long-term complications in patients treated for Hodgkin\u27s disease by O\u27Donnell, Susan James
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
1983
Long-term complications in patients treated for
Hodgkin's disease
Susan James O'Donnell
Yale University
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
O'Donnell, Susan James, "Long-term complications in patients treated for Hodgkin's disease" (1983). Yale Medicine Thesis Digital
Library. 2995.
http://elischolar.library.yale.edu/ymtdl/2995


Digitized by the Internet Archive 
in 2017 with funding from 
The National Endowment for the Humanities and the Arcadia Fund 
https://archive.org/details/longtermcomplicaOOodon 



Long-Term Complications in Patients Treated 
For Hodgkin's Disease 
by 
Susan Jane O'Donnell 
1983 
A Thesis Submitted to the 
of the Yale University School 
in Partial Fulfillment of the 
Faculty 
of Medicine 
Requirement 
for the Degree of Doctor of Medicine 
Med L-tb ■ 
'TnS 
4~Yl 
Acknowledgements 
I would especially like to thank Dr. Ed Cadman for the excellent 
advice and encouragement he gave me throughout the preparation of this 
thesis. 
I would also like to thank Dr. Leonard Prosnitz for allowing me 
access to the records and helping me to set up the project. 
I would finally like to thank the people in charge of records at the 
Departments of Radiotherapy at Yale, St. Raphael's Hospital and Uncas 
Hospital for their kind help in making all 297 charts available. 

Table of Contents 
Page 
I. Introduction 1 
II. Methods 4 
III. Results 9 
A. Second Malignancies 9 
B. Infections: Pneumonia, Meningitis and Sepsis 11 
C. Herpes Zoster Infections 21 
D. Thyroid Dysfunction 26 
E. Radiation Related Disorders 29 
F. Avascular Necrosis of Bone 31 
IV. Discussion 32 
V. References 51 

List of Tables 
Page 
1. Distribution of Patients by Stage of Disease 7 
2. Treatment of Patients with Hodgkin's Disease 8 
3. Second Malignancies in Patients Treated for Hodgkin's 10 
Disease 
4. Mortality Statistics 13 
5. Severe Infections in Patients Treated for Hodgkin's 14 
Disease 
6. Mortality Due to Infections: Its Relationship to 15 
Active Hodgkin's Disease and/or Treatment 
7. Treatment in Patients Who Developed Serious 16 
Infections 
8. Infections Agents in Pneumonia, Sepsis, and 17 
Meningitis 
9. Etiologic Agents of Pneumonia 18 
10. Etiologic Agents of Sepsis 19 
11. Etiologic Agents of Meningitis 20 
12. Distribution by Stage, of Patients with and 23 
Without Herpes Zoster Infections 
13. Treatment of Patients with and Without Herpes 24 
Zoster Infections 
14. Complications of Herpes Zoster Infections 25 
15. Hypothyroidism in Patients Treated for Hodgkin's 27 
Disease 
16. Hyperthyroidism in Patients Treated for Hodgkin's 28 
Disease 
17. Radiation Related Disorders 30 
18. Microorganisms with a Predilection for Individuals 38 
With Hodgkin's Disease 

Page 
42 19. Risk Factors for Herpes Zoster Infections in 
Hodgkin's Disease 
20. Incidence and Sequelae of Herpes Zoster - Varicella 43 
Infections in Hodgkin's Disease Patients 
21. Hypothyroidism in Hodgkin's Disease Patients 46 

1 
I. Introduction 
Hodgkin's disease, a malignant disease of lymphoreticular origin, almost 
invariably arises in lymph nodes and generally spreads contiguously. It is 
a relatively common malignancy with between 7000 and 8000 new cases diagnosed 
in the United States each year. Hodgkin's disease is a significant cause 
of morbidity and mortality in young people. It has an unusual bimodal age- 
specific incidence rate with one mode occurring at ages 15 to 35 years and 
the other above age 50 (34). 
Over the past twenty-five years, with the use of radiation therapy and 
with the introduction of combination chemotherapy in the early 1970's, the 
overall five year survival rate for Hodgkin's disease has gone from approx¬ 
imately 24% to as high as 75-85% in some centers (23,24). Many institutions 
are reporting 85% five year survival rates for localized disease (34) and 
some centers, such as Yale, have achieved 75% five year survival rates for 
patients with Stage IIIB and IV disease (30). While the outlook is not as 
good for patients whose disease recurs following chemotherapy, drug combin¬ 
ations have achieved complete remissions in up to 60% of patients treated. 
With careful evaluation and observation, perhaps 90 or 95% of patients who 
have survived free from relapse for five years are shown to be clinically 
cured of their disease (34). 
As Hodgkin's disease patients have achieved long-term survival and cure 
following treatment, the potentially adverse delayed side effects of therapy 
for Hodgkin's disease are assuming increasing importance both with respect 
to the type of therapy initially chosen and in the continued clinical care 
of these patients (2). As DeVita noted in his lecture on the consequences of 
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the chemotherapy of Hodgkin's disease, "While we often underrate the impact 
of [the acute adverse reactions to drug treatments], in truth, they are tragic 
only in circumstances when therapy does not work... While it may seem insen¬ 
sitive to say so, looking at long-term adverse effects is, in fact, a luxury 
that only follows successful treatment" (13). While the cure rates for 
Hodgkin's disease are increasingly optimistic, the long-term complications, 
particularly in this young population, may have great impact on the patient's 
health for years to come. 
There are several possible sources for these long-term side effects. Some 
complications, particularly infections, may be related to the disease itself. 
Patients with untreated Hodgkin's disease have a number of known abnormalities 
of the immune system including impairments manifested as prolonged tolerance 
of skin homografts, suboptima1 responses to cutaneous antigen stimulation, 
depressed T-cell numbers, impairment of lymphocyte function and serum factors 
which are inhibitory to normal lymphocytes (5). Of particular interest is 
that some of these immune abnormalities such as the defect in T-lymphocytes 
persist even in long-term survivors (13). Although unclear at present, these 
immune deficits could play a role in the development of long-term complications. 
Extensive staging procedures determine the treatment course for all patients. 
In recent years, however, complications related to these procedures have 
been recognized. The risk for post-splenectomy sepsis, for example, has been 
estimated to be as high as 3 to 10% in these patients (12). Another procedure, 
lymphangiography, probably increases the incidence of hypothyroidism following 
neck irradiation (39). Treatment itself, the source for cure in these patients, 
may also be a cause of some of the complications. Radiotherapy alone, 
particularly in high dose, extended field therapy, has been associated with 
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the later development of thyroid dysfunction and radiation related disorders 
of the lung, heart and other organs. Combined modality treatments of 
radiation and chemotherapy resulting in increased survival of patients 
with advanced disease, have also been found to be immunosuppressive and 
probably carcinogenic; the appearance of second malignancies in these 
patients is a matter of great concern. Avascular necrosis, an entity of 
great morbidity, has developed in patients receiving chemotherapy. 
The purpose of this present study is to take a group of Hodgkin's 
disease patients treated under standardized protocols with frequent, prolonged 
follow-up and to evaluate all major long-term complications, whether affected 
mainly by the underlying disease, the staging procedures or by the treatment 
with either radiation or radiation and chemotherapy. Each complication 
will be analyzed, when applicable, according to stage or state of activity 
of Hodgkin's disease, type of treatment and time course relative to treat¬ 
ment. These complications include second malignancies, serious infections 
such as pneumonia, sepsis or meningitis, herpes zoster infections, thyroid 
dysfunction, radiation related disorders andavascular necrosis of bone. 
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II. Methods 
Outpatient radiotherapy records of Hodgkin's disease patients 
treated by protocol (with a few non-protocol patients) and followed during 
the sixteen year period from 1966 to 1982 at the Yale University School 
of Medicine, St. Raphael's Hospital in New Haven and the Uncas Hospital 
in Norwich, CT., were reviewed for this study. All patients had a minimal 
follow-up period of two years. Data concerning age, sex, stage of disease, 
possible splenectomy, type of therapy and time course of therapy were noted. 
From a group of 323 patients who met these criteria, charts of 297 patients 
consisting of 136 females and 161 males were available for review. The 
median age of patients at initial diagnosis was 27.1 years with a range 
of 4 to 83 years. There were 47 deaths in this group of 297 patients with 
34 patients dying with disease and 13 patients having no evidence of disease 
at the time of death. All long-term complications were recorded. Temporary 
problems directly related to either the radiation or chemotherapy were not 
included. For each complication, the type of treatment, the relationship 
to therapy or activity of disease,and the possible risk factors were noted. 
Bacteriologic and viral studies, when available, were listed. The 
diagnosis of herpes zoster infections was usually made with a description 
of the lesions and associated symptoms, but in a few cases no clinical 
information was given; these cases were included since the diagnosis is 
generally based on clinical features. The patients who received the pneu¬ 
mococcal vaccine were determined, but since this was often administered 
by community physicians, the total number of patients receiving the vaccine 
is not available. Hypothyroidism, for the purposes of this study, was 
defined as an elevated thyroxine. The diagnosis of radiation related 
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disorders (i.e. radiation pneumonitis) was made by the attending radiolo¬ 
gist on the basis of roentgenegraphic changes and clinical symptoms. In 
many of the cases of radiation pneumonitis, although not all, the patients 
had a documented response to corticosteroids. 
The Ann Arbor staging system (6) was used for newly diagnosed patients 
and modified for the relapsed patients by addition of the prefix R before 
staging numerals. Table 1 gives the distribution of patients by stage 
of disease. As described by Prosnitz et.al. (29) staging procedures included 
the usual blood studies (cell count, serum electrolytes and liver function 
tests), chest film and tomograms in the presence of a mediastinal mass, 
lymphangiography with simultaneous iv pyelography, gallium and liver-spleen 
scans, bilateral iliac crest bone marrow aspirates and biopsies, and needle 
biopsy of the liver (initially closed, more recently via laparoscopy). 
In the early years of the study, all patients had a staging laparotomy in 
order to document the extent of disease; recently this has been changed 
so that laparotomy is no longer done for patients with clinical stage 
IIIB or Stage IV disease. In this study, 264 of the patients or 88.9% 
underwent laparotomy with splenectomy. 
Various treatment modalities were utilized according to the extent 
of disease. Radiation alone was used in 151 patients with localized disease. 
As described by Prosnitz et.al. (30) the fields used were the mantle and 
a full inverted Y field or a mantle and "spade field" (para-aortic nodes 
and splenic pedicle). When treating the mantle, doses were 3500-4500 rads, 
150-200 rads per fraction, five fractions weekly, both anterior and posterior 
fields treated daily. Multiagent chemotherapy with low dose irradiation 
(combined modality therapy) was administered to 75 patients with advanced 
disease. The chemotherapy consisted of mechlorethamine, vincristine. 
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vinblastine, procarbazine and prednisone (MVVPP) as outlined by Prosnitz 
et. al. (30) or of mechlorethamine, vincristine, prednisone and procarbazine 
(MOPP) as described by DeVita et. al. (14). The majority of patients 
received the MVVPP regimens consisting of five cycles of the five drugs, 
each cycle lasting about two months. After the third cycle, patients 
were restaged and those in complete remission were treated with low 
dose radiation (1500-2500 rads in 2-3 weeks time, five fractions weekly) 
to all areas of disease known to be present prior to onset of chemotherapy. 
Following radiation and a rest period of one month, patients received 
two additional cycles of chemotherapy (30). Since 1978 a group of patients 
with age greater than 40 years and/or stage IV disease with multiple 
extranodal sites of involvement received MVVPP or MOPP plus ABVD (doxo¬ 
rubicin, bleomycin, vinblastine and DTIC), since the data of the earlier 
period suggested such patients are a higher risk group for relapse and 
lower rate of response (29). Initial high dose irradiation was followed 
by combined modality therapy in 51 patients with relapse. Initial combined 
modality therapy was repeated at relapse in 7 patients. Thirteen patients 
with disease that relapsed received non-protocol treatments that included 
high dose irradiation followed by either chemotherapy alone, by low dose 
radiation therapy or by a non-protocol combination chemotherapy with irra¬ 
diation (Table 2). 
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Table 1 
Distribution of Patients by Stage of Disease 
Stage # Patients % 
IA 51 17.2 
RIA 3 1.0 
I IA 70 23.6 
RI IA 23 7.7 
I+IIB 14 4.7 
RI+IIB 13 4.4 
11 IA 29 9.8 
RIIIA 29 9.8 
II IB 26 8.6 
IVA 8 2.7 
RIVA 1 0.3 
IVB 27 9.1 
RIVB 3 1.0 
297 
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Table 2 
Treatment of Patients vyith Hodgkin's Disease 
# Cases 7o 
Radiation 151 50.8 
Radiation/chemotherapy 76 25.6 
★ 
Radiation-*- radiation/chemotherapy 51 17.2 
Radiation-* chemotherapy (non-protocol) 7 2.4 
Radiation/chemotherapy -* 2.0 
Radiation/chemotherapy 
Radiation -* radiation (Non-protocol) 4 1.3 
Radiation-* radiation/chemotherapy 2 0.7 
(Non-protocol) 
* [-* indicates "followed by treatment at relapse"] 
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III. Results 
A. Second Malignancies 
Second malignancies, one of the most serious complications that developed 
in this group of patients treated for Hodgkin's disease, included three 
cases of acute nonlymphocytic leukemia (ANLL), one case of diffuse histio¬ 
cytic lymphoma, two cases of thyroid carcinoma and one case of granulocytic 
sarcoma (Table 3). The three cases of ANLL followed successful treatment 
of relapsed Hodgkin's disease. The first case occurred in a thirty-four 
year old female treated with irradiation followed by a non-protocol chemo¬ 
therapy regimen at relapse for stage RIIA disease. The other two cases 
occurred in patients, aged twenty-three and twenty-nine, treated with com¬ 
bination chemotherapy and irradiation for stage 11 IB disease. The time 
interval from initial treatment of Hodgkin's disease to diagnosis of 
leukemia was 66 months in the first patient and 45 and 95 months in the 
other two patients. Diffuse histiocytic lymphoma occurred in one twenty- 
seven year old patient treated with irradiation followed by unsuccessful 
combination chemotherapy and irradiation for stage RIIB disease. The disease 
was discovered at the time of death, 34 months after his initial treatment 
for Hodgkin's disease. Thyroid carcinoma developed in two patients; the first 
case occurred 55 months after successful radiation treatment for stage 11A 
Hodgkin's disease and the second case occurred 141 months after combination 
chemotherapy and irradiation for advanced Hodgkin's disease. Granulocytic 
sarcoma was found in the neck of one patient in a region of prior irradiation 
following combined modality treatment for stage IVB Hodgkin's disease and 
was successfully treated. 
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Table 3 
Second Malignancies in Patients Treated for Hodgkin's Disease 
# Cases 
Mortality 
Prior Treatment 
Radiation (RT) 
Radiation/ 
chemotherapy 
RT^radiation/ 
chemotherapy 
RT->chemotherapy 
(NP)* 
Leukemia 
(ANLL) 
3 
3 
Lymphoma 
(DHL) 
1 
1 
Thyroid 
Ca 
2 
0 
Sarcoma 
(granulocytic) 
1 
0 
Time interval 
(in mos) 
45,95 
66 
34 55 
141 
111 
*NP=non-protocol 
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B. Infections: Pneumonia, Sepsis and Meningitis 
Infections were a cause of significant morbidity and mortality in those 
patients treated for Hodgkin's disease. Among the thirty-five patients 
who died with disease, infections were noted to be the proximate cause 
of death in six patients. All three patients with ANLL eventually died 
of infections. There were two patients in remission of Hodgkin's disease 
and without ANLL who died of infection (Table 4). Pneumonia was the most 
common form of severe infection occurring in 20 patients (6.7% total 
patients), followed by sepsis in 7 patients (2.4%) and meningitis in 5 
patients (1.7%) (Table 5). The relationship between the development of 
these infections and the activity of Hodgkin's disease was studied (Table 
6). In the group of 20 patients who developed pneumonia, 12 patients had 
active disease (7 patients under initial treatment and 5 patients with 
recurrent disease) and 8 patients were in remission. The deaths from 
pneumonia included 3 patients with active disease and 3 patients in re¬ 
mission (3 of these patients had ANLL). The episodes of pneumonia developed 
with a range of 1 to 97 months after the most recent Hodgkin's disease 
treatment and with a median of 11 months. More cases of sepsis occurred 
in patients with active disease (5 patients) than in remission (2 patients). 
Sepsis was fatal in 1 patient with active recurrent disease and in 2 patients 
in remission (one of whom had ANLL). Sepsis developed from 6 to 59 months 
following Hodgkin's disease treatment and with a median of 17 months. 
Meningitis occurred in 3 patients with active recurrent disease and in 
2 patients in remission. It was fatal in 2 patients, both of whom had 
active recurrent disease. Meningitis developed from 10 to 47 months after 
the most recent Hodgkin's disease treatment with a median duration of 

12 
22 months. A summary of the types of treatment in the patients who de¬ 
veloped these serious infections is found on Table 7. Although several 
cases of pneumonia occurred in patients who received radiation alone, 
six out of the seven fatal cases occurred in patients who received 
combined modality treatment. Sepsis and meningitis were both less fre¬ 
quent in patients who received radiotherapy alone. 
A broad range of bacterial, viral, fungal and parasitic organisms 
were cultured in these infections (Table 8). The etiologic agents for 
pneumonia included four cases due to pneumococcus, one case each due to 
Staphlyococcus aureus. Cytomegalovirus, Aspergillus and Pneumocystis 
carinii, and twelve cases with unspecified cultures (Table 9). Sixteen 
or 80% of the patients who developed pneumonia had undergone splenectomies. 
The organisms causing sepsis included three cases due to pneumococcus, 
one case due to a mixed flora of Herellea, Aerobacter and Enterobacter 
cloaca, one case due to a mixed flora of Staph aureus and unspecified 
gram negative rods, and one case each due to Aspergillus and herpes zoster 
(Table 10). The underlying cause of meningitis was found to be the 
pneumococcus in two patients and H. influenza. Cryptococcus or unspecified 
in the remaining three patients (Table 11). All of the patients who 
developed sepsis or meningitis had undergone splenectomy. Both patients 
with pneumococcal meningitis (one of whom developed pneumococcal sepsis 
as well) had received the pneumococcal vaccine; however, the organisms 
were typed and found to be of a strain not included in the vaccine. 
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Table 4 
Mortality Statistics 
Cause of death # Patients 
Hodgkin's disease 34 
Hodgkin's disease alone 26 
Infection 6 
Diffuse Histiocytic Lymphoma 1 
Lung Carcinoma 1 
Hodgkin's disease in remission 13 
Myocardial infarction 5 
ANLL and infection 3 
Lung carcinoma 2 
Meningioma 1 
Pneumonia 1 
Sepsis* 1 
*(This patient was undergoing chemotherapy; however autopsy showed no 
evidence of disease). 
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Table 5 
Severe Infections 
Infection # 
in Patients 
Cases 5 
Treated for Hodgkin1 
& Total Infections 
's Disease 
% Total Patients 
Pneumonia 20 62.5 6.7 
Sepsis 7 21.9 2.4 
Meningitis 5 15.6 1.7 
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Table 6 
Mortality Due to Infections: Its Relationship 
Disease and/or Treatment 
Infection Active HD Active HD(recurrent) 
(initial) 
to Active Hodgkin1s 
Remission Total 
Pneumonia #cases 7 5 
mortality 1 2 
Sepsis #cases 3 2 
mortality 0 1 
Meningitis #cases 0 3 
mortality 0 2 
20 
7 
7 
3 
5 
2 
3includes 3 patients with ANLL 
includes 1 patient with ANLL 
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Table 7 
Treatment in Patients Who Developed Serious Infections 
Pneumonia 
Treatment # Cases Mo rta 1 i ty 
Radiation (RT) 7 1 
Radiation/Chemotherapy 7a 3a 
RT->radi at i on/chemotherapy 4 2 
RT+chemotherapy (non-protocol) 2b ib 
Sepsis 
Treatment # Cases Mortality 
Radiation (RT) 1 0 
Radiation/chemotherapy 2 1 
RT+radiation/chemotherapy 2 0 
RT-*RT (non-protocol) 1 1 
RT-K;hemotherapy (non-protocol) ib ib 
Meningitis 
Treatment # Cases Mortality 
Radiation (RT) 1 0 
Radiation/chemotherapy 1 0 
RT+radiation/chemotherapy 3 2 
(includes two patients with ANLL) 
b (includes one patient with ANLL) 
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Table 8 
Infectious Agents in Pneumonia, Sepsis and Meningitis 
# Cases 
Bacterial Pneumococcus 9 
Staph aureus 2 
H. inf1uenza 1 
Herellea 1 
Aerobacter 1 
Enterobacter cloaca 1 
Gram negative rods (unspecified) 1 
Vira1 Herpes zoster 1 
Cytomegalovirus 1 
Fungal Aspergillus 2 
Cryptococcus 1 
Parasitic Pneumocystis carinii 1 
Unspecified 12 
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Table 9 
Etiologic Agents of Pneumonia 
# Cases 
Bacterial Pneumococcus 4 
Staph aureus 1 
Vi ral Cytomegalovirus 1 
Fungal Aspergi11 us 1 
Parasitic Pneumocystis carinii 1 
Unspecified 13 
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Table 10 
Etiologic Agents of Sepsis 
# Cases 
Bacterial Pneumococcus 3 
Herellea3 1 
Aerobacter3 1 
Enterobacter cloaca3 1 
Staph aureus0 1 
Gram negative nodes^ 1 
Vi ral Herpes zoster 1 
Fungal Aspergillus 1 
Parasitic 0 
(a and b represent two cases with mixed flora) 

20 
Table 11 
Etiologic Agents of Meningitis 
# Cases 
Bacterial Pneumococcus 2 
H. influenza 1 
Vira1 0 
Fungal Cyrptococcus 1 
Parasitic 0 
Unspecified 1 
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C. Herpes Zoster and Varicella Infections 
Herpes zoster infections represented the most common complication in 
this study and developed in 76 patients (25.6%); recurrences developed in 
only two patients (2.6%). One patient developed a varicella infection. 
The age of patients developing the infections ranged from 10 to 66 years 
with a median age of 26.5 years. This was comparable to the median age 
of patients who did not develop the infections, 27.2 years. Herpes 
zoster occurred with nearly equal frequency in both sexes with 40 males 
(52.6%) and 36 females (47.4%); the ratio of patients not developing 
infection was 121 males (54.8%) and 100 females (45.2%). Sites of 
involvement included facial nerve involvement in 5, ophthalmic in 3, 
cervical dermatome in 14, thoracic in 28, lumbar in 6, sacral in 3, 
disseminated in 9 and an unspecified location in 16 cases (six episodes 
overlapped two sites). 
The incidence of herpes zoster infections was then examined according 
to stage and treatment of disease. An analysis of stage, found on Table 12, 
demonstrates the highest frequency of zoster (22 patients or 29%) in patients 
with Stage III disease, followed by Stage II disease (15 patients or 19.7%), 
Stage I disease (9 patients or 11.8%) and finally stage IV disease (5 
patients or 6.6%). An increased incidence of zoster is found among all 
stages of relapsed disease (32.8% total) with highest frequency in R111A 
disease (11 patients or 14.5). The type of treatment was then evaluated 
for its influence upon the incidence of zoster (Table 13). Thirty-eight 
patients (50.0%) received radiation therapy alone, 23 patients (30.3%) 
received combination chemotherapy with irradiation (CRT), 12 patients 
(15.8%) underwent radiation followed by CRT at a later date, 2 patients 
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underwent radiation followed by a non-protocol radiation treatment and 
1 patient underwent radiation followed by a non-protocol CRT treatment. 
An analysis of the time interval from the initiation of treatment to 
the onset of viral infection reveals a median interval of 12.8 months with 
a range of 1 to 90 months and with 73.4% of the cases occurring within 
the first two years. Among patients whose Hodgkin's disease relapsed, 
there were five patients who developed herpes zoster infections at the 
time that relapse was discovered. 
Although the majority of cases were localized, unilateral, dermatomal 
infections, more serious complications did occur (Table 14). Dissemination, 
characterized by widespread vesicular lesions, occurred in nine patients 
(11.4%) including one fatal case in a 54 year old patient with active, re¬ 
lapsed disease. Of note, all nine cases of dissemination occurred within 
the group of fifteen patients who developed zoster infections after re¬ 
lapsed seminated infections. Seven of the nine patients were undergoing 
treatment for relapse at the time of infection. Three of these patients 
progressed to die of Hodgkin's disease (two patients died less than two 
months after infection; one patient died five years later). Pain, sig¬ 
nificant enough to be noted, was reported in 11 cases (13.9%) with an 
average duration of 2.5 weeks. Post herpetic neuralgia developed in 
two patients. Ophthalmic involvement occurred in three cases (3.4%) 
and resulted in residual mydriasis and decreased vision in one patient. 
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Table 12 
Di stribution by Stage, of Patients With and Without 
Herpes Zoster Infections 
Patients With Zoster Patients Without Zoster 
Stage # patients % # patients % 
IA 9 11.8 42 19.0 
RIA 1 1.3 2 0.9 
11 IA 12 15.8 58 26.2 
RIIA 9 11.8 14 6.3 
I+IIB 3 3.9 11 5.0 
RI+IIB 3 3.9 10 4.5 
11 IA 11 14.5 18 8.1 
RIIIA 11 14.5 18 8.1 
11 IB 11 14.5 15 6.8 
IVA 0 0 8 3.6 
RIVA 1 1.3 0 0 
IVB 5 6.6 22 10.0 
RIVB 0 0 3 1.4 
76 221 
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Table 13 
Treatment of Patients With and Without Herpes Zoster Infections 
Patients 
Zoster 
with Patients 
Zoster 
Without 
#patients l #patients % 
Radiation (RT) 38 50.0 113 51.1 
Radiation/chemotherapy 23 30.3 53 24.0 
RT+radiation/chemotherapy 12 15.8 39 17.6 
RT^chemotherapy(non-protocol) 0 0 7 3.2 
Radiation/chemotherapy -* 
radiation/chemotherapy 
1 1.3 5 2.3 
RT^RT (non-protocol) 2 2.6 2 0.9 
RT+radiation/chemotherapy 
(non-protocol) 
0 0 2 0.9 
76 221 
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Table 14 
Complications of Herpes Zoster Infections 
# Cases % 
Dissemination 9 11.4 
Death 1 1.3 
Ophthalmic Involvement 3 3.4 
Post Herpetic Neuralgia 2 2.5 
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D. Thyroid Dysfunction 
Hypothyroidism developed in 44 patients (14.8%). The age at treat¬ 
ment initiation in patients who subsequently became hypothyroid ranged 
from 11 to 65 years with a median age of 26.9 years. This was comparable 
to the median age of patients who did not become hypothyroid, 27.0 years. 
There was a female predominance among the hypothyroid patients; 28 patients 
were female (63.6%) and 16 patients were male (36.4%). This differed from 
the male: female ratio among the euthyroid patients, which was 145 males 
(57.3%) to 108 females (42.7%). 
Table 15 analyzes these patients according to treatment. Thirty-three 
patients (75.0%) received radiation alone, five patients received radiation 
and chemotherapy (11.4%), five patients underwent initial radiation followed 
by radiation and chemotherapy at relapse (11.4%) and one patient had radiation 
with a non-protocol radiation and chemotherapy treatment (2.2%). An analysis 
of the time interval from the initiation of treatment to the onset of hypo¬ 
thyroidism reveals a median interval of 31.5 months with a range of 3 to 
116 months. 
Hyperthyroidism developed in 5 patients (Table 16). The median age for 
this group of patients was 29 years with a range of 12 to 46 years. There 
were three females and two males. Three of the patients received radiation 
alone and two of the patients received radiation and chemotherapy. The 
time interval for the development of hypothyroidism ranged from 11 to 62 
months with a median of 55 months. One of the patients developed hypothyroid¬ 
ism 38 months before she became endogenously hyperthyroid. A second 
patient was found to have thyroid cancer shortly after the hyperthyroidism 
was discovered. 
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Table 15 
Hypothyroidism in Patients Treated for Hodgkin's Disease 
Total # % 
Patients 44 14.8 
female 28 63.6 
male 16 36.4 
Median age (yrs) 26.9 
Treatment 
Radiation (RT) 33 75.0 
Radiation/chemotherapy 5 11.4 
RT->radi ati on/chemotherapy 5 11.4 
RT+radiation/chemotherapy (non-protocol) 1 2.2 
Median time interval (mos) 31.5 
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Table 16 
Hyperthyroidism in Patients Treated for Hodgkin's Disease 
Total # 
Patients 5 
female 3 
male 2 
Median age (yrs) 29 
Treatment 
radiation 3 
radiation/chemotherapy 2 
Median time interval (mos) 55 
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E. Radiation Related Disorders 
Inflammatory processes felt to be related to radiation treatment occurred 
in the forms of pneumonitis, pericarditis, gastritis, enteritis, and nephritis 
(Table 17). There were 17 episodes of radiation pneumonitis in 16 patients 
(5.4% patients treated). Of these patients, 12 received radiation therapy 
alone, 3 underwent initial radiation followed by radiation and chemotherapy 
at relapse and 2 underwent combined modality therapy alone. There were 13 
episodes of presumed radiation pericarditis in 12 patients (4.0% patients 
treated). One of these patients required pericardiectomy for constrictive 
pericarditis and another patient underwent pericardiocentesis following 
tamponade. Eight of the patients had received prior radiotherapy alone, 
three patients had undergone initial radiation followed by radiation and 
chemotherapy at relapse and two patients had received radiation and chemo¬ 
therapy alone. The two patients who developed radiation gastritis had 
received radiotherapy singly. Radiation enteritis occurred in two patients; 
one patient had received solely radiotherapy and the other patient had re¬ 
ceived radiation and chemotherapy. Radiation nephritis occurred in only one 
patient, after irradiation alone. The median time interval for these in¬ 
flammatory and fibrotic reactions to develop in the patients treated with 
radiation was approximately three months for the episodes of pneu¬ 
monitis, gastritis and enteritis; 8.5 months for the episodes of pericarditis 
and 93 months for the patient who developed nephritis. 
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Table 17 
Radiation Related Disorders 
Pneumonitis Pericarditi s Gastritis Enteritis Nephri ti s 
# Cases 17 13 2 2 1 
Treatment 
Radiation(RT) 
Radiation/ 
12 8 2 1 1 
chemotherapy 
RT->radiation/ 
2 2 1 
chemotherapy 3 3 
Median time 
interval(mos)* 
Radiation(RT) 
Radiation/ 
3.5 8.5 3.0 3 93 
chemotherapy 
RT-*radiation/ 
4.0 unspec. 10 
chemotherapy 11.0 13.0 
*dated from relapse where applicable. 
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F. Avascular Necrosis of Bone 
Avascular necrosis of bone developed in four patients. The major 
site of involvement was the femoral head in all four patients (bilaterally 
in two cases) and two patients had humoral head involvement as well. One 
patient ultimately required bilateral hip replacement. All four patients 
had received chemotherapy which included prednisone; three patients had 
received initial radiation followed by combination chemotherapy with 
radiation for relapsed disease; one patient had received combination 
chemotherapy with radiotherapy for advanced disease. The median time 
interval from initial treatment with chemotherapy to the diagnosis of 
aseptic necrosis was 38.0 months with a range of 27 to 68 months. 

32 
IV. Discussion 
Second malignancies developing after successful treatment of Hodgkin's 
disease, although infrequent, are of major concern. A report by Cadman 
et. al. (5) estimated a 1% incidence of leukemia in treated Hodgkin's 
disease patients. Their data suggested that aggressive therapy of Hodgkin's 
disease promotes the development of ANLL not only at an increased rate, 
but also within a shorter interval of time than does less aggressive therapy. 
In this present study, there were three cases of ANLL in patients who had 
all received aggressive Hodgkin's disease therapy for advanced disease. 
Consistent with the greater risk noted for combined treatment (9), there 
were no patients in this study who developed ANLL following radiation alone. 
After the risk of developing ANLL was recognized, reports of increased 
rates of another second malignancy appeared, non-Hodgkin's lymphoma. 
Krikorian et. al. (22) noted the risk of its occurrence appeared similar 
to that of leukemia and was higher in the group of patients receiving both 
radiation therapy and chemotherapy. In this present study, there was one 
case of diffuse histiocytic lymphoma in a patient who had received both 
treatments for advanced disease. Unfortunately, all four of these patients 
with leukemia and lymphoma followed the general trend of having very aggres¬ 
sive and rapidly fatal diseases. A second malignancy with significantly 
fewer consequences is thyroid carcinoma. The occurrence of thyroid cancer 
after low dose irradiation to the neck has been recognized for almost 30 
years (24). Until recently, however, it was felt that doses of radiation 
in excess of 2000 rads (such as during Hodgkin's disease treatment) would 
either destroy the follicular cells or, at least, interfere with their 
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ability to divide. In 1980, however, McDougall et. al. (24) reported 
the occurrence of three cases of thyroid carcinoma among a series of 544 
Hodgkin's disease patients. The disease developed an average of 10 years 
after receiving 3000-4100 rads to the neck. Although the cited latent 
period from time of irradiation to documentation of thyroid cancer is 
usually 10-30 years (24), one of the patients in the Yale study showed 
evidence of disease in a shorter time interval (55 months). The relative 
risk and latent period for this newly recognized late complication of 
Hodgkin's disease treatment requires additional study. 
Patients with Hodgkin's disease are susceptible to a variety of in¬ 
fections due to both the impairment of cell-mediated immunity, which is 
integral to the disease itself, and to the immunosuppressive effects of 
radiotherapy and/or chemotherapy (21). Since the majority of patients have 
undergone splenectomy, there is additional risk of fulminant septicemia 
from encapsulated bacteria such as Streptococcus pneumoniae and Hemophi1 us 
influenza. In this series, infections were a significant cause of mortality; 
17% of patients dying from Hodgkin's disease had infections as a proximate 
cause of death and 8% of patients in remission died from infection. Similar 
to work by Schimpff et. al. (36), this study also indicated that pneumonia 
was the most common severe infection; sepsis was the next most frequent 
infection seen in long-term follow-up. Schimpff's study, however, reported 
no instances of meningitis, but did cite major wound infections as a sig¬ 
nificant source of morbidity, not seen in this study. In Schimpff's study, 
all the serious bacterial infections occurred in patients with recurrent 
Hodgkin's disease and persistent granulocytopenia (36). In this present 
study, however, serious infections were seen throughout the course of the 
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disease (Table 6). Patients with active disease, whether during initial 
therapy or during treatment for recurrences, did have more infections than 
those in remission; nevertheless, even if the patients in remission with 
ANLL are excluded from the analysis, there were several episodes of pneu¬ 
monia (one fatal), one episode of fatal sepsis and two cases of meningitis 
in this group. In addition to the effects of the underlying Hodgkin's 
disease, the post-splenectomy state and type of treatment influences the 
risk of infection. Since the vast majority of patients in this study 
underwent splenectomy (89%), no comparisons could be made. Schimpff's 
study noted that Streptococcus pneumoniae and Hemophilus spp infections, 
the organisms associated with post-splenectomy patients, were distinctly 
uncommon during the remission period (36). This trend was not seen in 
the Yale study (Table 8). Weitzman and Aisenberg (44) in their study, 
reported as in other large series, that sepsis was rare in post-splenectomy 
patients. They noted in their study of 160 patients with Hodgkin's disease, 
that all episodes of sepsis (3 cases with 2 deaths) occurred in the small 
group of 14 post-splenectomy patients who received total nodal radiation, 
and combination chemotherapy. They suggested that the additional inter¬ 
ventions of combination chemotherapy and total nodal irradiation, which 
do not significantly predispose to infection by themselves, add independent 
potentiating risks in the splenectomized subject. The data on Table 7 
suggest more serious infections in those treated with combined modality 
treatment. 
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Armstrong and Chmel (3) note that as the immune deficits that accompany 
Hodgkin's disease and its treatment change, so do the types of microorgan¬ 
isms responsible for infection. They note that early in the disease patients 
are more likely to be susceptible to microorganisms which have a predilection 
for individuals with mononuclear cell defects. However, as the disease and 
immunusuppression progresses, the susceptibility broadens and organisms 
infecting patients with neutrophile and opsonizing antibody defects then 
infect patients with far advanced, heavily treated Hodgkin's disease. On 
Table 18 is a list of microorganisms with a known predilection for indivi¬ 
duals with Hodgkin's disease which can be compared to Table 8 listing the 
organisms seen in this study. Tuberculosis, once an almost invariable 
finding at autopsy and said to "follow Hodgkiin's disease like a shadow" 
(41), is no longer common. Armstrong and Chmel (3) note that pneumonias 
in Hodgkin's disease can be caused by the usual organisms that cause pneu¬ 
monia in normal individuals, as well as facultative or obligate intracellu¬ 
lar parasites and fungi. Of the eight classified cases of pneumonia in our 
study, three were due to organisms more common in immunosuppressed hosts: 
Cytomegalovirus, Aspergillus and Pneumocystis carinii (Table 9). The or¬ 
ganisms responsible for sepsis in our study included pneumococci in three 
out of seven episodes as well as Aspergillus, herpes zoster, a mixed Herellea, 
Aerobacter and Enterobacter cloaca infection, and a mixed Staph aureus and 
gram negative rod infection. Desser and Ultmann's study (15) of post¬ 
splenectomy sepsis in 1170 patients found 14 episodes of bacteremia not re¬ 
lated to toxicity of chemotherapy or to the immediate postoperative period. 
In their study, as in ours, approximately half of the episodes of sepsis were 
due to pneumococci. According to Armstrong and Chmel (3) the most common 
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cause of meningitis in patients' with Hodgkin's disease is Cryptococcus 
neoformans followed closely by Listeria monocytogenes. In this study, 
while one out of four episodes of meningitis was due to Cryptococcus, 
the remaining cases (two episodes due to the pneumococcus and one due to 
H. influenza) were more typical of meningitis in the post-splenectomy 
patient in particular. In summary, the occurrence of infections in the 
Hodgkin's disease patient is influenced by immune deficits secondary to 
disease itself, to treatment and to possible splenectomy. Besides con¬ 
tinued efforts for early detection and appropriate management of the 
infections, primary prevention is the ultimate goal. Aggressive, combined 
modality treatments responsible for the significant improvement in sur¬ 
vival from Hodgkin's, must be continually reviewed and refined as necessary. 
Thorough immunological testing and assessment, as it becomes available,could 
possibly identify patients at increased risk for infections. Splenectomy, 
due to its important function in staging of the disease and determining 
treatment, has generally been felt to be worth the risks of infection 
for clinical stage I-111. Dailey et.al. (12) concluded that splenic 
irradation, suggested by some investigators as an alternative to surgical 
removal, was not a benign alternative. They reported on the development 
of splenic atrophy and sepsis following irradiation alone. Since pneumococci 
are a major organism involved in post-splenectomy sepsis, administration of 
the pneumococcal vaccine is generally recommended for these patients. This 
polyvalent vaccine first become available at Yale in February 1978, although 
the exact number of patients who have received it, is unclear from the 
records. Two patients in this study, however, did develop pneumococcal 
disease from a strain not included in the vaccine. This occurrence has been 

37 
noted by other investigators as well (1). Minor et. al. (25) have 
reported on the problem of poor or inconsistent antibody response to the 
vaccine in Hodgkin's disease patients. They recommend administering the 
vaccine prior to splenectomy and the initiation of treatment,as well as 
monitoring pneumococcal antibody levels after vaccination to define the 
patients at greatest risk for developing sepsis. 

38 
Bacterial 
Fungal 
Parasites 
Vi ruses 
aStreptoco 
patients 
Table 18 
Microorganisms with a Predilection for Individuals With 
Hodgkin's Disease (3) 
Listeria monocytogenes 
Salmonella species 
Nocardia asteroides 
Mycobacteriurn tuberculosis 
Streptococcus pneumoniae5 
Cryptococcus neoformans 
Histoplasma capsulatum 
Cocci diodes immitis 
Candida albicans 
Pneumocystis carinii 
Toxoplasma gondii 
Strongyloides stercoral is 
Hartmanella species 
Herpes simplex virus 
Cytomegalovirus 
Varicella-zoster virus 
Vaccinia virus 
ecus pneumoniae and Hemophilus influenza infect Hodgkin's disease 
following splenectomy. 
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Herpes zoster was the most prevalent infection as well as the most 
common complication to develop in these Hodgkin's disease patients. Herpes 
zoster infections are believed to represent a reactivation of a virus that 
has remained latent within spinal ganglia following a previous episode of 
varicella (32). Ragozzine et. al. (31), in a recent study of herpes zoster 
in the general population found that cancer was the most common risk fac¬ 
tor for the infections (6% of the entire cohort) followed by trauma (2%), 
radiotherapy (1.5%), chemotherapy (0.3%), systemic steroids (0.3%) and 
surgery (0.2%). In a study of 419 patients at the Baltimore Cancer Re¬ 
search Center (37), zoster occurred in 25% of patients with Hodgkin's 
disease, 8.7% of other lymphoma patients, but in only 1.2% of patients 
with acute leukemia and 1.8% of patients with solid tumors. The in¬ 
creased incidence of herpes zoster in patients with Hodgkin's disease 
was first recognized in 1924 (27). The most significant common factor 
responsible for the development of zoster in these patients is the depres¬ 
sion in cellular immunity (32). 
Various studies have examined the possible risk factors for the de¬ 
velopment of zoster in patients (Table 19). Although increasing age is 
associated with an increased incidence of zoster infections in the general 
population (31), the zoster patients in the Yale study had a median age of 
26.5 years, similar to that of the noninfected patients. The sex ratio of 
infected patients in the Yale study was approximately equal just as in 
the general population study (31). The influence of stage of disease on 
risk for herpes zoster is not totally clear. Reboul et. al. (33) noted an 
increased frequency of infections among patients with particularly Stage 
III but also Stage II and Stage IV disease as opposed to Stage I disease. 
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One could postulate a greater depression in cel 1-mediated immunity in 
patients with advanced disease resulting in greater risk for infection. 
The exact immune mechanisms involved in the reactivation of latent virus, 
however, are unknown. Studies by Schimpff et. al. (36) and Green et. al. 
(18), however, found stage of disease to be an insignificant factor. In 
the Yale study (Table 12), the distribution by stage of disease for pa¬ 
tients with and without herpes zoster infections showed the highest fre¬ 
quency in patients with Stage III disease. Since one would not expect the 
greatest immune depression in these patients, a possible explanation for this 
trend is that it is related to treatment. Reboul et. al. (33) noted an 
increased incidence of zoster in patients treated with extended, as 
opposed to limited, field irradiation. Many of the Stage III patients in 
the early years of the Yale study did receive total nodal (extensive field) 
irradiation. There was a trend toward more zoster infections among the Yale 
patients receiving irradiation as opposed to combined modalities. Green's 
study, however, showed the opposite trend (18). In all four studies, the 
time interval for greatest risk of infection was within the first two 
years (Table 19). The influence of splenectomy on the risk for zoster 
was not studied here, but was found not to be significant in the studies 
by both Reboul et. al. (33) and Green et. al. (18). Thus, it would appear 
that the relative risks for zoster due to stage of disease and treatment 
have yet to be fully determine, although multiple factors play a role in 
susceptibility to this complication. 
As can be found on Table 20, the incidence and sequelae of zoster in¬ 
fections are surprisingly common. The Yale study, like other recent studies 
shows a high rate of zoster infections. Dissemination is distinctly more 
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common in Hodgkin's disease patients than in the general population (31) 
and it is this complication that makes the prevention of zoster infections 
important. Zoster immune globulin has been used successfully in protecting 
immunosuppressed children against varicella (4), but it has not been fully 
studied for use in zoster infection. Since this study found patients with 
relapsed disease to be at greatest risk for dissemination, these patients 
might benefit from administration of hyperimmune globulin as prophylaxis 
against infection,and perhaps even after infection,in an attempt to reduce 
the risk of dissemination. 
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Hypothyroidism has long been recognized as a consequence of external 
beam radiation to the neck in patients with various carcinomas and lym¬ 
phomas. Despite the fact that lower doses of radiation are used in Hodgkin's 
disease, the frequency of hypothyroidism seems to be much higher in this 
group (39). The incidence of hypothyroidism is also noted to increase over 
time. Schimpff et. al. (35) found thyroid dysfunction in less than 15% of 
patients tested during the first year and a maximum of 66% reached at about 
6 years. The Yale study also showed this time related phenomenon with a 
median time interval of 31 months for hypothyroidism to develop. Glatstein 
and associates suggested that hypothyroidism was more frequent in patients 
who had had a lymphangiogram in addition to radiation therapy. This suggestion 
was based on a comparison of their patients with Hodgkin's disease who had 
had lymphangiography and a group of patients with head and neck cancer who 
had had no lymphangiogram before irradiation. It was postulated that the large 
iodine load of the lymphangiogram rendered the thyroid gland more radiosen¬ 
sitive (35). Smith et. al. (39), proponents of this theory, suggest that 
thyroxine suppression of the thyroid gland during the period from the lymphan¬ 
giogram through the termination of radiation therapy might be a means of 
avoiding thyroid injury. Further studies are needed to determine if other 
aspects of Hodgkin's disease and/or its treatment result in the high incidence 
of hypothyroidism in these patients. When hypothyroidism is defined as a 
depressed level of thyroxine, its incidence varies from 6.2% (39) to 20.1% 
(35) or higher (Table 21). The Yale study's finding of 14.8% of patients 
becoming hypothyroid is well within observed limits. More recently is has 
been recognized that thyroid-stimulating hormone (TSH) is always elevated 
before development of thyroxine depression. Thus, there is a period of 
compensated hypothyroidism in many patients before clinical hypothyroidism 
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develops (35). When elevated TSH levels are used to signify thyroid dsy- 
function, several studies showed up to two thirds of Hodgkin's patients 
meeting the criteria for hypothyroidism (39) (35) (42).Si nee there is some 
evidence that elevated TSH in the persence of irradiation damaged thyroid 
tissue can be carcinogenic, replacement therapy for patients with elevations 
of TSH alone is now being recommended (35). 
Autoimmune mechanisms may also be iinvolved in the development of thyroid 
dysfunction following Hodgkin's disease treatment. The female preponderance 
of hypothyroidism noted in the Yale study was previously reported by Vrabec 
and Heffron (42). One possible explanation for female susceptibility they 
gave was subclinical Hashimoto's thyroiditis, an entity three to four times 
more common in the female. They suggested a prospective study designed 
to clarify this possibility using pretreatment and serial post-treatment 
thyroid antibody studies. An entity that is far less frequent, with a 
limited number of reports in the literature, is Graves' disease following 
thyroid irradiation. Wasnich et. al. (43) gave the first report of the 
association of thyroid irradiation and Graves' disease. A possible explan¬ 
ation is that release of thyroid antigenic material secondary to the radiation 
damage results in the development of serum thyroid antibody, perhaps including 
long-acting thyroid stimulator (35). The five cases of hyperthyroidism fol¬ 
lowing Hodgkin's disease treatment at Yale are the largest series reported 
in the literature. The occurrence in one Yale patient of hypothyroidism followed 
by hyperthyroidism was also noted in a recent case report by Constine and 
McDougall (10). They hypothesized that their patient had an underlying auto¬ 
immune thyroid disease before initiation of radiation treatment for Hodgkin's 
disease. Thus, the periodic assessment of thyroid status should be part of 
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Table 21 
Hypothyroidism in Hodgkin's Disease Patients 
# Patients # Patients with hypothyroidism 
Smith et. al. (39) 64 4 (6.2%) 
Yale 297 44 (14.8%) 
Shalet et. al ■ (38) 32 5 (16.0%) 
Nelson et. al . (26) 50 10 (20.0%) 
Schimpff et. al. (35) 214 43 (20.1%) 
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the long-term observation of patients who have received thyroid irradiation, 
not only to exclude hypothyroidism (a: wel1-documented complication of thyroid 
irradiation) but also early Graves' disease (28). 
Long term effects of radiotherapy include radiation pneumonitis, peri¬ 
carditis, gastritis, enteritis and nephritis. A mild to moderate form of 
radiation pneumonitis occurred in 5.4% of the patients in the Yale Study. 
This type of pulmonary reaction was described by Kaplan and Stewart (21) 
as developing about 3 months after the completion of treatment. The media¬ 
stinal silhouette is noted to appear rather fuzzy and shaggy, and irregular 
strands of density become evident in the paramediastinal pulmonary parenchyma 
in a distribution corresponding to the size and shape of the mediastinal 
portion of the mantle field. Accompanied by these roentgenographic changes 
are the variable symptoms of dry cough with possible dyspnea. These patients, 
like those in the Yale study, had their symptoms persist for 2-4 months 
and then diminish following either no specific treatment or corticosteroids. 
The severity of radiation pneumonitis was found to be reduced by decreasing 
the volume of irradiated lung, the total dose, and the dose per fraction; with 
these changes, the incidence was reduced from 26 to 4% (21). This corresponded 
to the incidence in the Yale study. Kaplan and Stewart (21) also reported 
a number of patients with Hodgkin's disease who developed cardiomegaly, 
pericardial effusions, and other manifestations of radiation-induced heart 
disease. The clinical manifestations included acute pericarditis, often 
associated with pericardial effusion, sometimes with signs of tamponade, 
and occasionally progressing to chronic pericardial effusions and/or to 
constrictive pericarditis, sometimes requiring pericardiectomy. They noted 
(similar to the Yale study) that most symptoms appeared within the first 
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year after radiotherapy, but occasionally they were delayed for as long 
as 4 to 5 years. As in radiation pneumonitis, there is a clear-cut dose 
response for the incidence and severity of cardiac complications. Carmel 
and Kaplan (7) reported that with changes in the technical aspects of 
radiotherapy including shielding of the heart, the incidence of pericar¬ 
ditis was reduced from 17 to 4.8%. The 4% incidence of pericarditis in the 
Yale study corresponded to this observation. The clinical spectrum of delayed- 
appearing radiation-induced cardiac disease is only now being fully recog¬ 
nized. A recent study by Applefeld et. al. (2) used electrocardiograms, M- 
mode echocardiograms, exercise ECG-gated radionuclide ventriculography and 
cardiac catheterization to evaluate 25 Hodgkin's disease patients. In this 
group of patients, eight had constrictive pericarditis, eight had occult 
constrictive pericarditis, three had an abnormal response to fluid challenge, 
three had suspected or proven occlusive coronary artery disease and one 
each had a cardiomyopathy and diminished functional capacity on exercise 
testing. This unexpectedly high incidence of delayed-appearing cardiac 
disease necessitates further studies into the pathogenesis of radiation- 
induced disease and its relationship to the administration of chemotherapy. 
Statistical methods have not been used by Applefeld and others to determine 
if chemotherapy combined with radiotherapy can potentiate radiation induced 
cardiac disease. Other radiation-induced organ damage is far less frequent. 
Gastrointestinal complications such as gastritis and enteritis were uncommon 
in the Yale study as well as in others (36). Radiation nephritis, noted when 
doses to the kidneys exceeded 2500 rads, is now generally avoided (36). 
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Avascular necrosis develops as a result of impairment of the circulation 
of the affected bone and may involve either a single bone or several (30). 
It can be the source of considerable incapacity for the patient. Ihde and 
DeVita in 1975 first noted the association of femoral osteonecrosis and 
malignant lymphoma (10). Prosnitz et. al. (30) in a recent review of the 
complication at Yale (the 4 patients described here were part of that study) 
found that in the group of advanced Hodgkin's disease patients, the 
cumulative frequency in long-term survivors was a surprising 10% at ten 
years. Onset of symptoms in that study ranged from 6 to 78 months from 
the start of chemotherapy (mean 28 months). This is comparable to the 
time course noted by other investigators such as Thorne et. al. (40) who 
reported a mean of 34 months. The high incidence of avascular necrosis in 
Hodgkin's disease patients may be related to several factors. Cortico¬ 
steroids are most clearly implicated in the pathogenesis. Cruess (11), 
in a recent review of the subject, favors the hypothesis that the detri¬ 
mental affect of steroids is an alteration in fat metabolism. He notes that 
vascular occlusion and bone death may result from an increase in fat cell size 
or from fat embolization. In the Yale study, Prosnitz et. al. (30) reported 
that total prednisone doses as low as 3-6 g with a mean of 5.1 g were associated 
with the complication. The relative roles of the other chemotherapy agents 
and radiotherapy is less clear. There is one report of avascular necrosis 
following single agent chemotherapy use alone (Cytoxan) (10); probably though, 
the drugs act as potentiators. Whether radiotherapy, particularly in full doses, 
may also be a contributing factor is unknown (30). Thorne et. al. (40) reported 
on a single patient with Hodgkin's disease treated by pelvic radiation alone 
who developed avascular necrosis of the femoral head within one month of 
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irradiation. They suggested that radiation may have a deleterious effect 
on already compromised tissue, but they also postulated that Hodgkin's 
disease itself in an unknown manner, may predispose to the development of 
avascular necrosis. The relative roles of all these factors in the patho¬ 
genesis of avascular necrosis is to be determined in future studies. The 
prevention of avascular necrosis could involve altering the type and 
amount of chemotherapy agents including prednisone. Prosnitz et. al. 
suggest that if radiation is an etiologic factor, then shielding of the 
humeral head should reduce the frequency of shoulder involvement. Shielding 
the medial femoral heads from radiation, however, is not possible without 
blocking pelvic lymph nodes (30). Engel et. al. (16) recommend careful 
followup including periodic bone scan surveillance of the patients at 
greatest risk for the complication. They note that early conservative 
management, such as a course of nonweight bearing, may prevent permanent 
disability and reduce the number of patients requiring surgery. 
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